Vireo Growth (VREOF) Net Cash Flow Growth (1y) (2021 - 2026)
Vireo Growth (VREOF) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | -1,020.00% |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 383.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 383.33% |
| Dec 31, 2025 | -94.12% |
| Sep 30, 2025 | 387.38% |
| Jun 30, 2025 | 1,553.84% |
| Mar 31, 2025 | -60.68% |
| Dec 31, 2024 | 3,059.99% |
| Sep 30, 2024 | -302.53% |
| Jun 30, 2024 | -237.40% |
| Mar 31, 2024 | 30.04% |
| Dec 31, 2023 | 139.87% |
| Sep 30, 2023 | -59.97% |
| Jun 30, 2023 | -88.05% |
| Mar 31, 2023 | 26.71% |
| Dec 31, 2022 | -298.25% |
| Sep 30, 2022 | 153.84% |
| Jun 30, 2022 | 142.41% |
| Mar 31, 2022 | -148.71% |
| Dec 31, 2021 | -63.43% |
| Sep 30, 2021 | -185.71% |
| Jun 30, 2021 | -228.74% |